Physician profile
Ilya Leyngold
NPI 1407996176
$27,434.99
in general payments reported to CMS, 2019-2025
16 companies · $4,082 in 2025
The $4,082 reported for 2025 was more than what 85% of Ophthalmic Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $10K · 2021: $3,991 · 2022: $1,940 · 2023: $5,469 · 2024: $1,672 · 2025: $4,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,335 · Honoraria: $3,180 · Food and Beverage: $2,554 · Travel and Lodging: $1,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,335.00 |
| Honoraria | $3,180.00 |
| Food and Beverage | $2,554.34 |
| Travel and Lodging | $1,152.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axogen | $10,301.82 | 2019-2025 | Axoguard Nerve Protector, Axoguard Nerve Connector, Avance Nerve Graft |
| Horizon Therapeutics Plc | $7,698.47 | 2020-2023 | Tepezza |
| Osteomed LLC | $5,040.82 | 2020-2021 | |
| Amgen INC. | $3,153.89 | 2024-2025 | Tepezza |
| Mentor Worldwide LLC | $241.48 | 2024-2025 | Mentor Memorygel Resterilizable Gel Sizer, Stratafix |
| Revance Therapeutics, INC. | $209.57 | 2025 | Daxxify, Daxi |
| Argenx US, INC. | $125.17 | 2025 | Vyvgart |
| Galderma Laboratories, L.P. | $115.20 | 2023-2025 | Dysport |
| Abbvie INC. | $112.75 | 2023-2025 | |
| Depuy Synthes Sales INC. | $93.47 | 2022 | |
| Biotissue Holdings INC. | $90.92 | 2021-2022 | |
| Ethicon US, LLC | $74.70 | 2019 | |
| Boston Scientific Corporation | $54.71 | 2024 | Fineline II Sterox |
| Dompe US, INC. | $51.04 | 2019 | |
| Stryker Corporation | $42.90 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $28.08 | 2025 | Artiss |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ilya Leyngold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.